Nguyen Thi Ngoc Anh, Nguyen Van Phu Thang, Kurohama Hirokazu, Akazawa Yuko, Matsuda Katsuya, Mussazhanova Zhanna, Matsuoka Yuki, Yokota Kenichi, Satoh Shinya, Yamashita Hiroyuki, Nguyen Thi Nhung, Sailaubekova Yerkerzhan, Nakashima Masahiro
Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Department of Histology and Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Thyroid. 2024 Dec;34(12):1476-1485. doi: 10.1089/thy.2024.0310. Epub 2024 Oct 31.
The coexistence of v-Raf murine sarcoma viral oncogene homolog B1 () and telomere reverse transcriptase promoter (-p) mutations is considerably associated with aggressiveness and poor prognosis in papillary thyroid carcinoma (PTC). However, the association between gross findings and genetic alterations in PTC remains unknown. We aimed to investigate the association between clinicopathologic features, including macroscopic features, and the coexistent and -p mutations in patients with PTC. We retrospectively analyzed 375 cases of PTC surgically resected between January 2018 and October 2023 at a single institution, based on the presence of and -p double mutation. Clinicopathologic features, including gross features on the cut surface of tumors, were evaluated. Subsequently, the association between clinicopathologic features and mutation status was statistically examined. Cox proportional hazard models were used to analyze the impact of molecular pathological features on disease-free survival (DFS). The and -p double mutation was identified in 78 (20.8%) patients among the PTC cases and was significantly correlated with shorter DFS. Multivariable analysis revealed that factors such as relatively older age (≥55 years) (odds ratio [OR] = 12.083, 95% confidence interval [CI] 4.498-32.456), larger tumor size (>2.0 cm) (OR = 2.722, CI 1.104-6.712), lobulated tumor margins (OR = 16.114, CI 3.155-82.296), papillary excrescences on the cut surface (OR = 17.573, CI 3.462-89.201), solid-cut surface (OR = 4.012, CI 1.084-14.849), minimal extrathyroidal extension (ETE) (OR = 4.156, CI 1.209-14.282), gross ETE (OR = 6.517, CI 1.734-24.490), and Ki-67 labeling index (LI) (≥5%, OR = 12.145, CI 4.354-33.877) were significantly associated with the double mutation. The and -p double mutation in PTC was significantly associated with relatively old age, larger tumor size, lobulated configuration in tumor margin, papillary excrescences on the cut surface, solid-cut surface, ETE, and high Ki-67 LI. These features are suggestive of the presence of the double mutation and should be analyzed at the molecular level in patients with PTC.
v-Raf鼠肉瘤病毒癌基因同源物B1()与端粒逆转录酶启动子(-p)突变的共存与甲状腺乳头状癌(PTC)的侵袭性和不良预后密切相关。然而,PTC大体表现与基因改变之间的关联尚不清楚。我们旨在研究PTC患者的临床病理特征(包括宏观特征)与共存的和-p突变之间的关联。我们回顾性分析了2018年1月至2023年10月在单一机构手术切除的375例PTC病例,基于和-p双重突变的存在情况。评估了临床病理特征,包括肿瘤切面的大体特征。随后,对临床病理特征与突变状态之间的关联进行了统计学检验。使用Cox比例风险模型分析分子病理特征对无病生存期(DFS)的影响。在PTC病例中,78例(20.8%)患者检测到和-p双重突变,且与较短的DFS显著相关。多变量分析显示,相对年长(≥55岁)(比值比[OR]=12.083,95%置信区间[CI]4.498 - 32.456)、肿瘤较大(>2.0 cm)(OR = 2.722,CI 1.104 - 6.712)、肿瘤边缘呈分叶状(OR = 16.114,CI 3.155 - 82.296)、切面有乳头状赘生物(OR = 17.573,CI 3.462 - 89.201)、实性切面(OR = 4.012,CI 1.084 - 14.849)、最小甲状腺外侵犯(ETE)(OR = 4.156,CI 1.209 - 14.282)、大体ETE(OR = 6.517,CI 1.734 - 24.490)以及Ki-67标记指数(LI)(≥5%,OR = 12.145,CI 4.354 - 33.877)等因素与双重突变显著相关。PTC中的和-p双重突变与相对年长、肿瘤较大、肿瘤边缘呈分叶状、切面有乳头状赘生物、实性切面、ETE以及高Ki-67 LI显著相关。这些特征提示存在双重突变,在PTC患者中应进行分子水平分析。